Compare Abbott Laboratories (ABT) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Broadcom Inc — how do they compare? Abbott Laboratories trades at $108.75 (market cap $187.95B), while Broadcom Inc trades at $425.69 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 10.5× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | AVGO | |
|---|---|---|
Market Cap | $187.95B | $1.98T |
Sector | Health | Technology |
52-Week High | $136.62 | $481.57 |
52-Week Low | $82.57 | $289.60 |
Enterprise Value | $214.96B | $2.02T |
Dividend Yield | 2.32% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Broadcom (AVGO) trades at $422.4, down 1.25% on the day, but maintains a bullish technical trend with strong support at $418. The company reported robust earnings, beating estimates for three consecutive quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 forecast. Revenue growth accelerated to $63.89 billion in 2025, up from $51.6 billion in 2024, while net income surged to $23.13 billion. Valuation multiples remain elevated with a P/E of 69.23, reflecting high investor expectations for AI-driven growth.
Outlook remains positive given strong AI revenue projections exceeding $100 billion by 2027, but high valuation and dependence on a few large customers pose risks. Analyst consensus is overwhelmingly bullish with 86% buy ratings and a $510.21 price target, suggesting 21% upside. Competitive pressures in the semiconductor space and macroeconomic volatility are key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
